News & Articles

Antigen test reliably and quickly triages people suspected of SARS-CoV-2, with results ready in 15 minutes, allowing informed treatment decisions

Test delivers results in just 15 minutes with no instrumentation, using proven lateral flow technology with demonstrated sensitivity of 97.1% and specificity of 98.5%

Syndromic testing will streamline respiratory infection diagnosis as COVID-19 pandemic collides with start of flu season

The AI-Rad Companion Brain MR and Prostate MR measures volumetric changes in brain, and segments prostate for targeted biopsy under MRI and ultrasound fusion imaging respectively

The Somatom scanner is equipped with a forward-looking camera and motorized wheels, allowing a single technologist to navigate the device through hospital hallways

Access Anti-SARS-CoV-2 is an easy-to-use 10-minute test on a portable device that provides highly accurate results on total Ig antibodies

Join us on Tuesday, September 1, to learn about why patients are admitted to an intensive care unit and what is available in terms of physiological support, monitoring, and treatments

Learn about the potential of lateral flow assays in detecting symptomatic and asymptomatic COVID-19 infections

The partnership enables LUMICKS to expand on the implementation of the z-Movi to new immunotherapeutic settings

Trial supports Abbott's focus on being the best partner for electrophysiologists treating people living with atrial fibrillation

Exclusive interviews, new methods, free downloads, and much more to help you advance your work

87 percent of patients in ZUMA-2 pivotal trial responded to single infusion of Tecartus

The study is the first global, randomized, double-blind, placebo-controlled phase III trial investigating Actemra/RoActemra in this setting

The ViroKey™ SARS-CoV-2 RT-PCR Test v2.0 is a probe-based reverse transcription PCR test

The NeuroSphere Digital Care offers flexible virtual care options as the COVID-19 global pandemic impacts how healthcare is administered

Based on the results, the U.S.-based trial has been stopped, including in a second cohort of patients who received a higher dose of Kevzara (800 mg)

A new test being developed by Iceni Diagnostics promises a quick way to distinguish between the two diseases